Jazz Pharmaceuticals PLC (JAZZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jazz Pharmaceuticals PLC (JAZZ) has a cash flow conversion efficiency ratio of 0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($408.20 Million) by net assets ($4.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Jazz Pharmaceuticals PLC's balance sheet to measure how much of total assets are equity-financed.
Jazz Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Jazz Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check JAZZ cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Jazz Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jones Lang LaSalle Incorporated
NYSE:JLL
|
-0.102x |
|
Lifco AB (publ)
ST:LIFCO-B
|
0.036x |
|
IGM Financial Inc.
TO:IGM
|
0.016x |
|
BE Semiconductor Industries NV
AS:BESI
|
0.165x |
|
Pinnacle Financial Partners, Inc.
NYSE:PNFP
|
0.063x |
|
Regal Beloit Corporation
NYSE:RRX
|
0.024x |
|
Daqin Railway Co Ltd
SHG:601006
|
0.021x |
|
Metro Inc.
TO:MRU
|
0.078x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals PLC (2005–2025)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals PLC from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Jazz Pharmaceuticals PLC (JAZZ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.32 Billion | $1.36 Billion | 0.314x | -7.93% |
| 2024-12-31 | $4.09 Billion | $1.40 Billion | 0.341x | +16.69% |
| 2023-12-31 | $3.74 Billion | $1.09 Billion | 0.292x | -29.11% |
| 2022-12-31 | $3.09 Billion | $1.27 Billion | 0.412x | +109.95% |
| 2021-12-31 | $3.97 Billion | $778.51 Million | 0.196x | -20.13% |
| 2020-12-31 | $3.66 Billion | $899.65 Million | 0.246x | -1.50% |
| 2019-12-31 | $3.11 Billion | $776.40 Million | 0.250x | -13.86% |
| 2018-12-31 | $2.76 Billion | $798.90 Million | 0.290x | +13.41% |
| 2017-12-31 | $2.71 Billion | $693.09 Million | 0.255x | -18.79% |
| 2016-12-31 | $1.88 Billion | $590.54 Million | 0.315x | -5.47% |
| 2015-12-31 | $1.60 Billion | $531.94 Million | 0.333x | +12.45% |
| 2014-12-31 | $1.37 Billion | $405.76 Million | 0.296x | +35.17% |
| 2013-12-31 | $1.30 Billion | $283.62 Million | 0.219x | -1.71% |
| 2012-12-31 | $1.12 Billion | $249.75 Million | 0.223x | -71.67% |
| 2011-12-31 | $192.79 Million | $151.60 Million | 0.786x | -59.19% |
| 2010-12-31 | $30.55 Million | $58.87 Million | 1.927x | +783.83% |
| 2009-12-31 | $-72.83 Million | $-15.88 Million | 0.218x | -84.45% |
| 2008-12-31 | $-92.88 Million | $-130.23 Million | 1.402x | +195.09% |
| 2007-12-31 | $54.99 Million | $-81.09 Million | -1.475x | -553.30% |
| 2006-12-31 | $-176.30 Million | $-57.35 Million | 0.325x | -26.26% |
| 2005-12-31 | $-118.25 Million | $-52.16 Million | 0.441x | -- |
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more